FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1870209870> ?p ?o ?g. }

• W1870209870 endingPage "3568" @default.
• W1870209870 startingPage "3556" @default.
• W1870209870 abstract "Ritonavir is a protease inhibitor utilized primarily as a pharmaco-enhancer with concomitantly administered antiviral drugs including other protease inhibitors. However, poor tolerance, serious side effects, and toxicities associated with drug-drug interactions are common during exposure to ritonavir. The aim of this work was to investigate the impact of nanoformulation on ritonavir pharmacological properties. Emulsion-templated freeze-drying techniques were used to generate ritonavir (10 wt %) solid drug nanoparticle formulations. A total of 68 ritonavir formulations containing various mixtures of excipients were assessed for inhibition of CYP3A4 in baculosomes and primary human hepatocytes. Accumulation and cytotoxicity were assessed in HepG2 (hepatocytes), Caco-2 (intestinal), THP-1 (monocytes), A-THP-1 (macrophage), and CEM (lymphocytes). Transcellular permeation across Caco-2 cells was also assessed. From 68 solid drug nanoparticle formulations tested, 50 (73.5%) for baculosome and 44 (64.7%) for human primary hepatocytes exhibited enhanced CYP3A4 inhibition relative to an aqueous ritonavir solution. Sixty-one (89.7%) and 49 (72%) solid drug nanoformulations had higher apical to basal permeation across Caco-2 cells than aqueous solution of ritonavir after 60 and 120 min, respectively. No significant difference in cellular accumulation was observed for any solid drug nanoparticle for any cell type compared to aqueous ritonavir. However, incubation with the vast majority of solid drug nanoparticle formulations resulted in lower cytotoxicity of ritonavir than detected with an aqueous solution. These data provide in vitro proof of concept for improved inhibition of CYP3A4 by ritonavir through formation of solid drug nanoparticles. Nanodispersions also showed enhanced permeability across Caco-2 cells lower cytotoxicity across hepatic, intestinal, and immune cell types compared to an aqueous solution of ritonavir." @default.
• W1870209870 created "2016-06-24" @default.
• W1870209870 creator A5022406499 @default.
• W1870209870 creator A5044415887 @default.
• W1870209870 creator A5045044657 @default.
• W1870209870 creator A5046489228 @default.
• W1870209870 creator A5058761939 @default.
• W1870209870 creator A5066429649 @default.
• W1870209870 creator A5072130830 @default.
• W1870209870 date "2015-09-18" @default.
• W1870209870 modified "2023-10-18" @default.
• W1870209870 title "Augmented Inhibition of CYP3A4 in Human Primary Hepatocytes by Ritonavir Solid Drug Nanoparticles" @default.
• W1870209870 cites W1505616359 @default.
• W1870209870 cites W1906145619 @default.
• W1870209870 cites W1964015173 @default.
• W1870209870 cites W1972463444 @default.
• W1870209870 cites W1976580747 @default.
• W1870209870 cites W1977324053 @default.
• W1870209870 cites W1977509284 @default.
• W1870209870 cites W1978360672 @default.
• W1870209870 cites W1979192842 @default.
• W1870209870 cites W1990609423 @default.
• W1870209870 cites W1991916654 @default.
• W1870209870 cites W1992092592 @default.
• W1870209870 cites W1996139192 @default.
• W1870209870 cites W1996141149 @default.
• W1870209870 cites W1997154876 @default.
• W1870209870 cites W1999711931 @default.
• W1870209870 cites W2000113946 @default.
• W1870209870 cites W2000966246 @default.
• W1870209870 cites W2003623971 @default.
• W1870209870 cites W2004639120 @default.
• W1870209870 cites W2006051612 @default.
• W1870209870 cites W2012487371 @default.
• W1870209870 cites W2016687070 @default.
• W1870209870 cites W2017404902 @default.
• W1870209870 cites W2035168432 @default.
• W1870209870 cites W2041587333 @default.
• W1870209870 cites W2042046525 @default.
• W1870209870 cites W2043305969 @default.
• W1870209870 cites W2046330571 @default.
• W1870209870 cites W2055332875 @default.
• W1870209870 cites W2055576047 @default.
• W1870209870 cites W2055645153 @default.
• W1870209870 cites W2055904567 @default.
• W1870209870 cites W2060648309 @default.
• W1870209870 cites W2061106944 @default.
• W1870209870 cites W2067288122 @default.
• W1870209870 cites W2068854073 @default.
• W1870209870 cites W2068946470 @default.
• W1870209870 cites W2075144974 @default.
• W1870209870 cites W2078387155 @default.
• W1870209870 cites W2083067873 @default.
• W1870209870 cites W2089338386 @default.
• W1870209870 cites W2090365405 @default.
• W1870209870 cites W2090884085 @default.
• W1870209870 cites W2095552493 @default.
• W1870209870 cites W2096844288 @default.
• W1870209870 cites W2104270610 @default.
• W1870209870 cites W2104804170 @default.
• W1870209870 cites W2106308893 @default.
• W1870209870 cites W2106408660 @default.
• W1870209870 cites W2106600662 @default.
• W1870209870 cites W2109189857 @default.
• W1870209870 cites W2109313097 @default.
• W1870209870 cites W2109818488 @default.
• W1870209870 cites W2111668019 @default.
• W1870209870 cites W2118699123 @default.
• W1870209870 cites W2121690400 @default.
• W1870209870 cites W2122280827 @default.
• W1870209870 cites W2122733948 @default.
• W1870209870 cites W2129568931 @default.
• W1870209870 cites W2132654534 @default.
• W1870209870 cites W2147235996 @default.
• W1870209870 cites W2153195414 @default.
• W1870209870 cites W2155219251 @default.
• W1870209870 cites W21607863 @default.
• W1870209870 cites W2162287902 @default.
• W1870209870 cites W2162742015 @default.
• W1870209870 cites W2164349191 @default.
• W1870209870 cites W2167865974 @default.
• W1870209870 cites W2325746679 @default.
• W1870209870 cites W2330372519 @default.
• W1870209870 cites W2416703940 @default.
• W1870209870 cites W3023255929 @default.
• W1870209870 doi "https://doi.org/10.1021/acs.molpharmaceut.5b00204" @default.
• W1870209870 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26348830" @default.
• W1870209870 hasPublicationYear "2015" @default.
• W1870209870 type Work @default.
• W1870209870 sameAs 1870209870 @default.
• W1870209870 citedByCount "15" @default.
• W1870209870 countsByYear W18702098702016 @default.
• W1870209870 countsByYear W18702098702017 @default.
• W1870209870 countsByYear W18702098702018 @default.
• W1870209870 countsByYear W18702098702019 @default.
• W1870209870 countsByYear W18702098702021 @default.
• W1870209870 countsByYear W18702098702022 @default.
• W1870209870 crossrefType "journal-article" @default.

• next